News

Fri, 16/02/2018
Muenster scientists present their latest research
Muenster.  The Scientific Retreat of the SFB CRC-TR 128 will be held on the 9th and 10th of March 2018. PhD students and young postdocs from all labs of the Department of Neurology and Insititute for Translational Neurology in Münster will give short oral presentations summarizing their main ongoing projects. Sessions will be introduced by […]...more
Fri, 16/02/2018
Ion channels in autoimmune neurodegeneration
Muenster. Autoaggressive T Lymphocytes that have to cross the activated blood brain barrier (BBB) play an important role in the pathogenesis of MS. Prof. Sven Meuth, principal investigator in the DFG-funded cluster of excellence “Cells in Motion” and the CRC 128 “Multiple Sclerosis” focusses on the potassium channel TREK-1. It analyses the molecular pathways through […]...more
Fri, 16/02/2018
Introduction into Histopathology of MS
Muenster, The CRC-128 „Multiple Sclerosis“ offers an histopathology course for its members. The two-day seminar is open for nine selected participants who will get the chance to learn neuropathology techniques and join a microscopy session. Where?: Institute of Neuropathology, Pottkamp 2, 48149 Muenster When?: April 26-27, 2018 flyer histopathology muenster 2018  ...more


Tue, 16/09/2014 | How adhesion molecules help pathogenic T cells to find their way over the blood-brain-barrier

Münster scientists: Even a highly efficacious MS drug cannot stop certain inflammatory cells

It all started with unexpected cells in the cerebrospinal fluid of MS patients and it ended with a discovery by neuro-immunologists at the university of Münster that could lead to an improved therapy against MS and other incurable autoimmune diseases.

The scientists lead by Univ.-Prof. Dr. med. Heinz Wiendl and Dr. rer. nat. Nicholas Schwab analyzed blood and CSF of patients, who had been treated with a highly efficacious MS drug, the monoclonal antibody natalizumab. This drug works by inhibiting the central pathogenic mechanism in MS: the invasion of pathogenic T cells over the blood-brain-barrier into the CNS, where they damage the tissue. The substance natalizumab inhibits this invasion by blocking very-late-antigen (VLA)-4, which serves as a key for the cells to unlock the blood-brain-barrier. Without VLA-4 there could be no pathogenic T cells in the CSF and CNS – at least this was the state of the art prior to the discovery of the Münster scientists.

“We were very surprised to find a detectable number of T cells in the CSF of natalizumab patients” explains Co-PI Dr. Nicholas Schwab. Looking more closely, it became apparent that on the few cells in the CSF of natalizumab patients, there was no VLA-4. “The drug works as it is supposed to. However, what kind of cells are these cells without VLA-4? And how can they invade the CNS?” asks Schwab.

In their search for answers, Prof. Wiendl and his team found the adhesion molecule MCAM. “We found a lot of MCAM molecules in the CSF of long-term treated natalizumab patients,” Wiendl explains. “The molecule seems to be something like a fallback mechanism that the cells use to adhere to the blood-brain-barrier”.

This function of MCAM was not known until then, but explains a series of experimental and clinical observations in recent years. For example it has been known for some time that patients, who stop treatment with natalizumab, suffer from severe MS relapses. The cause of this is not completely understood. Now the scientists from Münster believe that these relapses might be triggered by MCAM-expressing cells. If a patient is under therapy with natalizumab, the drug exclusively blocks VLA-4 and leads to the inhibition of T helper cell invasion of the CNS – cells that subsequently cannot mediate further damage to the tissue. This leads to patients who are free from relapses and disease progression. During natalizumab therapy, however, other dangerous cells can enter the CNS: those expressing MCAM. Without help, these cells cannot do much harm in the brain and spinal cord. However, if the drug is no longer administered, the combined cell populations can mediate damage even more effectively. “The sentinel MCAM cells are already in place, when the remaining T cells regain their key to the CNS,” Wiendl explains.

To prove that MCAM is the key for these cells into the CNS, the scientists blocked both VLA-4 and MCAM in experiments. “Under these conditions, pathogenic cells could no longer adhere to the blood-brain-barrier” Schwab explains.

Whether this therapeutic approach can be used in clinical practice is difficult to predict. Even now, the drug natalizumab on its own can lead to severe adverse effects, because it weakens the immune system. If remaining molecules were also shut off, there could be unforeseen consequences for the immune system. This is one reason to pursue the surprising discovery in follow-up projects in collaboration (as they did in the current article) with Prof. Dr. med. Alexander Zarbock from the Max-Planck-Institute for moleculare biomedicine. The project is funded by the DFG SFB TR128 (Multiple Sclerosis) and SFB 1009 (“Breaking Barriers”) and is part of the excellence cluster “Cells in motion” (CiM).

MCAM could be the key to other inflammatory diseases as well. “We are thinking of other putatively Th17-mediated diseases such as the optic nerve inflammation in neuromyelitis optica, where natalizumab does not work” Dr. Tilman Schneider-Hohendorf explains. He is first author of the article, which has been published in the most recent issue of the renowned Journal of Experimental Medicine.